MAMU
JAZZ icon

Myriad Asset Management US’s Jazz Pharmaceuticals JAZZ Stock Holding History

Myriad Asset Management US’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-15,400
Closed -$2.4M – 34
2022
Q2 		$2.4M Buy
+15,400
New +$2.37M 0.55% 22

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Myriad Asset Management US's JAZZ Position: Q3 2022 in Review

Myriad Asset Management US sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2022, closing a stake of 15,400 shares — an estimated $2.4M sold.

Myriad Asset Management US first reported a position in JAZZ in Q2 2022 and held it in 1 quarter. The position peaked at $2.4M in Q2 2022. 468 funds tracked by Wall St. Rank hold JAZZ as of Q3 2022.

  • Myriad Asset Management US reported no remaining Jazz Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Myriad Asset Management US sold 15,400 Jazz Pharmaceuticals shares in Q3 2022, an estimated $2.4M.
  • Myriad Asset Management US first reported a position in Jazz Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Myriad Asset Management US's Jazz Pharmaceuticals position peaked at $2.4M in Q2 2022.
  • 468 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2022.

Based on Myriad Asset Management US's 13F filing for Q3 2022, filed 14 Nov 2022.